AHC
REGN icon

Adell Harriman & Carpenter’s Regeneron Pharmaceuticals REGN Stock Holding History

Adell Harriman & Carpenter’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-480
Closed -$252K – 179
2025
Q2 		$252K Buy
480
+4
+0.8% +$2.23K 0.02% 157
2025
Q1 		$302K Sell
476
-27
-5% -$18.6K 0.02% 150
2024
Q4 		$358K Hold
503
– – 0.02% 138
2024
Q3 		$529K Hold
503
– – 0.04% 121
2024
Q2 		$529K Sell
503
-4
-0.8% -$3.88K 0.04% 117
2024
Q1 		$488K Hold
507
– – 0.04% 128
2023
Q4 		$445K Buy
507
+126
+33% +$104K 0.04% 123
2023
Q3 		$314K Hold
381
– – 0.03% 141
2023
Q2 		$274K Sell
381
-8
-2% -$6.17K 0.03% 150
2023
Q1 		$320K Buy
389
+32
+9% +$24.1K 0.03% 145
2022
Q4 		$258K Hold
357
– – 0.03% 156
2022
Q3 		$246K Buy
+357
New +$225K 0.03% 157
2022
Q2 		– Sell
-360
Closed -$251K – 166
2022
Q1 		$251K Sell
360
-1
-0.3% -$633 0.02% 160
2021
Q4 		$228K Buy
+361
New +$222K 0.02% 170

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adell Harriman & Carpenter's REGN Position: Q3 2025 in Review

Adell Harriman & Carpenter sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 480 shares — an estimated $252K sold.

Adell Harriman & Carpenter first reported a position in REGN in Q4 2021 and held it in 14 quarters. The position peaked at $529K in Q3 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Adell Harriman & Carpenter reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Adell Harriman & Carpenter sold 480 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $252K.
  • Adell Harriman & Carpenter first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 14 quarters.
  • Adell Harriman & Carpenter's Regeneron Pharmaceuticals position peaked at $529K in Q3 2024.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Adell Harriman & Carpenter's 13F filing for Q3 2025, filed 4 Nov 2025.